West Pharmaceutical Adjusts 2024 Guidance Amid Sales Dip
Company Announcements

West Pharmaceutical Adjusts 2024 Guidance Amid Sales Dip

An announcement from West Pharmaceutical Services ( (WST) ) is now available.

West Pharmaceutical Services reported a slight decline in third-quarter 2024 net sales to $746.9 million and a drop in adjusted earnings per share to $1.85 from $2.16 last year. Despite these declines, the company raised its full-year sales and EPS guidance due to favorable currency movements. West’s proprietary products segment saw a minor sales decline, while contract-manufactured products experienced slight growth. The company also announced a dividend increase, continuing its long-standing annual dividend growth tradition.

For a thorough assessment of WST stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyWest Pharmaceutical rises 21.8%
TheFlyEarly notable gainers among liquid option names on October 24th
TheFlyWest Pharmaceutical rises 15.2%
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App